Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female participants greater than or equal to (\>=) 18 years of age.~2. Participants must have undergone an orthopedic procedure (that is, total knee or hip replacement, spinal fusion, or reduction of fracture(s) with or without surgical fixation post trauma).~3. Participants must be receiving opioid analgesics (a mu agonist only-not to include agents with mixed mechanisms of action such as tramadol or buprenorphine) after the procedures and be expected to require daily opioid analgesics for at least 7 days post randomization.~4. Participants must be acutely constipated following their orthopedic procedure.~5. Participants must receive all doses of study drug in either hospitals or rehabilitation facilities.~6. Participants must sign an informed consent form.~7. Females of childbearing potential must have a negative pregnancy test and use appropriate birth control throughout the study.~8. Body weight within range of 40 kilograms (kg) - 150 kg (88 - 330 pounds \[lbs\]).~Exclusion Criteria:~1. Participants with known hypersensitivity to methylnaltrexone, naltrexone, or naloxone.~2. Participants who received any investigational new drug (experimental) in the previous 30 days.~3. Participants who have received a laxative (for example, lactulose) or an enema within 48 hours prior to the first dose.~4. Participants with constipation not attributed to post procedure opioids.~5. Participants with a history of alcohol or prescription or non-prescription drug abuse within the past 2 years.~6. Female participants who are pregnant or lactating.~7. Participants with a known history of chronic active hepatitis B or hepatitis C virus or human immunodeficiency virus (HIV) infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MNTX (Type: EXPERIMENTAL): Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) subcutaneously (SC) once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching to MNTX SC once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).